KeyBanc upgraded Health Catalyst to Overweight from Sector Weight with a $16 price target, which represents 23% upside from current levels. The stock’s current valuation is "very attractive" given the early stages of improving fundamentals for Health Catalyst’s core hospital end markets, the analyst tells investors in a research note. The firm believes this should bode well for the company’s top- and bottom-line trends versus consensus expectations.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HCAT:
- Health Catalyst initiated with an Equal Weight at Stephens
- Health Catalyst announces partnership with Contexture
- Health Catalyst upgraded to Overweight from Equal Weight at Wells Fargo
- Health Catalyst price target lowered to $16 from $17 at Citi
- Health Catalyst to Participate in Upcoming Investor Conference
